Genta, Inc. (GNTA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA)

GNTA 2.300

+0.4%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Nobrega who started this subject	6/3/2003 6:27:22 PM
From: bob zagorin	of 1870

Aventis says Europeans to start Genasense trial PARIS, June 3 (Reuters) - Franco-German drugmaker Aventis <AVEP.PA> said on Tuesday a study showed Genta Inc.'s <GNTA.O> anti-cancer drug Genasense aided its Taxotere drug in fighting prostate cancer and that a trial of the drug combination was planned. Data showed Genasense amplified the activity of Taxotere in prostate cancer, particularly when patients received Genasense before chemotherapy, Aventis and U.S. drug company Genta said in a joint statement. Genasense inhibits the production of Bcl-2, a protein that is believed to be a fundamental cause of resistance to anticancer therapy, the companies said. Overall, 14 of the 29 patients in the trial had a greater than 50 percent reduction in blood levels of prostate specific antigen -- a standard measure of the extent of prostate cancer. The European Organisation for the Research and Treatment of Cancer, a leading European cancer cooperative, would begin a new Phase II multicenter trial of the Genasense-Taxotere combination in patients with hormone refractory prostate cancer, they said. 06/03/03 11:37 ET

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next